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A B S T R A C T
Objective: We aimed to study the inﬂuence of carbapenem resistance on attributable mortality in a
cohort of patients with Pseudomonas aeruginosa bacteremia.
Methods: Data on 121 episodes of P. aeruginosa bacteremia occurring between January and December
2005 were retrospectively analyzed.
Results: Thirty-three episodes were caused by carbapenem-resistant P. aeruginosa (CRPA) strains and 88
by carbapenem-susceptible P. aeruginosa (CSPA) strains. There was no signiﬁcant difference in mortality
between the groups (33% in CRPA vs. 30% in CSPA; p = 0.69). However, a Kaplan–Meier survival analysis
showed that in the ﬁrst 48 h after the onset of bacteremia, there was a lower cumulative mortality
proportion in the CRPA group than in the CSPA group (13% vs. 50%; p = 0.026). The independent risk
factors associated with death in P. aeruginosa bacteremia were clinical presentation with severe sepsis
(odds ratio (OR) 38, 95% conﬁdence interval (CI) 10.2–142.2) and bacteremia of high-risk origin (OR 6.6,
95% CI 1.6–26.9).
Conclusions: According to our data, carbapenem resistance was not associated with higher mortality in
patients with P. aeruginosa bacteremia. The slower initial mortality in the CRPA group might have
implications in the design of the optimal antibiotic policy strategy.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journa l homepage: www.e lsev ier .com/ locate / i j id1. Introduction
Pseudomonas aeruginosa bacteremia remains one of the most
serious hospital-acquired infections, with amortality ranging from
20% to 38%.1–3 In recent years, several surveillance studies from
Europe and the USA have reported increasing antimicrobial
resistance rates in P. aeruginosa isolates, usually involving
intensive care units (ICUs), but also affecting general wards and
outpatient populations.4–7
The deleterious effects of the emergence of antimicrobial
resistance on several patient outcomes, such as length of hospital
stay or healthcare costs, arewell known. The detrimental impact of
resistance on mortality, however, has been repeatedly ques-
tioned.8,9 Although it is presumed that infections caused by
antimicrobial-resistant bacteria result in higher mortality than§ This manuscript was presented in part at the 46th Interscience Conference on
Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 27–30,
2006 (abstract number K-0522).
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1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.11.019those caused by susceptible strains, this intuition has not always
been conﬁrmed.10,11 It has been hypothesized that this theoretical
relationship between mortality and resistance may be attributed
to a higher probability of receiving initially inappropriate
antimicrobial therapy, leading to a delay in effective treatment.12
Nevertheless, some authors argue that the use of appropriate
empirical therapy before susceptibility results are available may
not be so critical to patient outcomes, since mortality in
bacteremia caused by Gram-negative organisms in general, and
by P. aeruginosa in particular, is mainly related to other factors,
such as the high-risk focus of the infection or clinical presentation
with sepsis or shock.13–15
At our hospital, epidemiological surveillance of antibiotic-
resistant pathogens has revealed a worrying increase in carbape-
nem-resistant P. aeruginosa strains in recent years. A preliminary
analysis found that over 10% of these strains caused bacteremia
and, moreover, that the mortality of patients with bacteremia
caused by these strains was greater than 30% (46th Interscience
Conference on Antimicrobial Agents and Chemotherapy, 2006,
abstract K-0522). In this study we evaluated the impact of
carbapenem resistance on mortality in a cohort of patients with P.
aeruginosa bacteremia.ses. Published by Elsevier Ltd. All rights reserved.
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2.1. Setting, study design, and data collection
The study was carried out at the Hospital de Bellvitge, a 900-
bed, tertiary-care teaching hospital for adults in Barcelona, Spain,
and focused on episodes of bacteremia due to P. aeruginosa
occurring between January and December 2005. A retrospective
cohort study was conducted. The main hypothesis was that
patients with an episode of P. aeruginosa bacteremia caused by
carbapenem-resistant strains would have greater mortality than
those with carbapenem-susceptible strains. The primary outcome
was attributable mortality. Episodes of bacteremia were identiﬁed
from the clinical microbiology laboratory database, and pertinent
data were retrieved from patient hospital charts. Episodes were
allowed to enter the cohort more than once only if subsequent P.
aeruginosa bacteremia occurred after a previous properly treated
and cured episode, so that it could be considered as an independent
episode.
The following data were collected: age, sex, healthcare system
contact using previously deﬁned criteria, duration of hospital stay
before bacteremia; underlying disease according to crude Charlson
co-morbidity index,16 antimicrobial therapy during the month
prior to bacteremia, neutropenia, use of corticosteroid or other
immunosuppressive agent; presence of vascular or urinary
catheter, mechanical ventilation, or history of an invasive
procedure or surgery during the month prior to bacteremia;
severity of illness in ICU patients, estimated by the simpliﬁed acute
physiology score (SAPS II);17 source of bacteremia according to the
Centers for Disease Control and Prevention (CDC) criteria.18
2.2. Deﬁnitions
P. aeruginosa bacteremia met the CDC criteria for infection.18
Carbapenem-resistant P. aeruginosa (CRPA) was deﬁned in those
isolates with an imipenem minimum inhibitory concentration
(MIC) 8 mg/l, irrespective of susceptibility to meropenem.
Bacteremia was considered nosocomially acquired if it occurred
at least 48 h after hospital admission and there was no evidence of
infection before then. Healthcare-associated bacteremia was
deﬁned by the criteria of Friedman et al.19 Neutropenia was
deﬁned by an absolute neutrophil count of<0.5 109 cells/l before
the onset of infection. Patients were considered to have previous
immunosuppression if chemotherapy, radiotherapy, or immuno-
suppressive agents were administered in the 30-day period
preceding the bacteremia episode. For the purpose of the analyses,
the source of bacteremia was classiﬁed into two categories, as
described earlier: high-risk source (unknown origin, lower
respiratory tract, abdominal, and soft tissue sources) and low-
risk source (intravenous catheter or urinary tract sources).20
Previous deﬁnitions of severe sepsis21 were modiﬁed to include
patients with septic shock, coagulopathy, or multiple organ
dysfunction syndrome (MODS).
Empirical antimicrobial therapy was deﬁned as the antibiotic
therapy received by the patient between the time the index blood
culture was drawn and the antibiotic susceptibility testing results
were available. Deﬁnitive antimicrobial therapy was antimicrobial
therapy given after antimicrobial susceptibility was reported.
Antimicrobial therapywas considered appropriate if at least one of
the antimicrobial drugs given was later proved to be active in vitro
against the P. aeruginosa isolate, provided it had been administered
at the current recommended dose and pattern of administration.
For purposes of the evaluation of the appropriateness of
antimicrobial therapy, patients who had not received antimicro-
bial therapy – neither empirical nor deﬁnitive –were classiﬁed into
a separate category. Regardless of the in vitro antimicrobialsusceptibility, monotherapy with an aminoglycoside was consid-
ered an inappropriate treatment for P. aeruginosa pneumonia.22
Non-antimicrobial therapy was deﬁned as the removal of vascular
or urinary catheters as well as surgical or percutaneous drainage of
purulent collections, when these were considered the source of
bacteremia and deemed necessary to solve the infection. Overall
mortality was deﬁned as death for any reason within 30 days after
the onset of the bacteremia. Attributable mortality was considered
when it occurred within the ﬁrst 7 days from the onset of
bacteremia and after excluding other causes of death.
2.3. Microbiological laboratory methods
Gram-negative, oxidase-positive bacilli growing on blood agar
and MacConkey agar were identiﬁed as P. aeruginosa by
standardized methods for the detection of Gram-negative bacilli.
Antimicrobial susceptibility was performed by an automated
microdilution method (MicroScan; Dade International Inc., West
Sacramento, CA, USA) and the Etest method (AB Biodisk, Solna,
Sweden). The antibiotics tested were: piperacillin, piperacillin–
tazobactam, ticarcillin, ceftazidime, cefepime, aztreonam, imipe-
nem, meropenem, ciproﬂoxacin, gentamicin, tobramycin, amika-
cin, and colistin. The Clinical and Laboratory Standards Institute
(CLSI) criteria were used to determine the susceptibility threshold
breakpoints of tested antibiotics against P. aeruginosa.23 Isolates
with intermediate susceptibility according to these criteria were
considered resistant.
2.4. Statistical analyses
We considered attributable mortality as the main outcome in
all the analyses performed. To examine the relationship between
carbapenem resistance and mortality, all the cases in the cohort
were included in the analysis (model 1). To better examine the
appropriateness of empirical antimicrobial therapy, a second
analysis was performed excluding those cases that had not
received empirical antimicrobial therapy, as the inﬂuence of
antibiotic treatment in this group was considered not evaluable
(model 2). Analysis of the inﬂuence of deﬁnitive antimicrobial
treatment on mortality was not performed because of the small
sample size.
Comparative analyses were done with the Chi-square test or
Fisher’s exact test for assessment of differences in proportions, and
the Student’s t-test for the continuous variables, as appropriate.
Continuous variables are given as mean (standard deviation) or
median (range), depending on the distribution. Kaplan–Meier
failure curves were plotted and compared between different
groups by the log-rank, Breslow, and Tarone–Ware tests. For
multivariate analyses, the Cox proportional hazard model was the
ﬁrst choice, but after checking that the proportional hazards
assumption was not satisﬁed, we used multiple logistic regression
analyses for this purpose. Variables for which p was <0.10 in the
bivariate analyses or those with a plausible biological relationship
to the outcome were considered candidates for multivariate
analyses. Results of the logistic regression analyses are reported as
odds ratios (OR) with 95% conﬁdence intervals (CI). All tests were
two-tailed, and p < 0.05 was considered to indicate statistical
signiﬁcance. SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) was
used for the statistical analyses.
3. Results
3.1. Demographic and clinical characteristics
There were 121 episodes of P. aeruginosa bacteremia occurring
in 116 patients (93 males and 23 females), whose median age was
Table 1
Clinical and epidemiological characteristics of 121 patients with Pseudomonas aeruginosa bacteremia, according to carbapenem susceptibility
Characteristic CSPA (n = 88) CRPA (n = 33) p-Value
Length of hospitalization, days (range) 9 (2–56) 19 (2–98) 0.03
Charlson index >2 38 (43%) 13 (39%) 0.71
SAPS, mean (SD) 40 (15) 44 (15) 0.43
Immunosuppression 26 (30%) 12 (36%) 0.47
Neutropenia 10 (11%) 2 (6%) 0.63
Vascular catheter 56 (64%) 23 (70%) 0.53
Urinary catheter 48 (55%) 20 (61%) 0.60
Mechanical ventilation 28 (32%) 15 (46%) 0.16
Previous surgery 34 (39%) 14 (42%) 0.70
Polymicrobial bacteremia 25 (28%) 6 (18%) 0.25
Previous antimicrobial therapy 58 (66%) 32 (97%) <0.001
Carbapenems 10 (11%) 9 (27%) 0.03
Fluoroquinolones 15 (17%) 14 (42%) 0.004
Source of bacteremia
Catheter 20 (23%) 10 (30%) 0.55
Urinary 23 (26%) 10 (30%)
Unknown/endogenous 23 (26%) 8 (24%)
Intra-abdominal 6 (7%) 2 (6%)
Respiratory 13 (15%) 3 (9%)
Soft tissue 3 (3%) 0 (0%)
Severe sepsisa 32 (36%) 14 (42%) 0.57
Antimicrobial treatment
Empirical treatment
Appropriate 57 (65%) 11 (33%) 0.004
Inappropriate 21 (24%) 18 (55%)
Deﬁnitive treatment
Appropriate 60 (68%) 15 (46%) <0.001
Inappropriate 3 (3%) 8 (24%)
Non-antimicrobial therapy 35 (40%) 19 (58%) 0.09
30-day mortality 32 (36%) 15 (46%) 0.36
Attributable mortality 26 (30%) 11 (33%) 0.69
CSPA, carbapenem-susceptible P. aeruginosa; CRPA, carbapenem-resistant P. aeruginosa; SAPS, simpliﬁed acute physiology score; SD, standard deviation.
a Includes septic shock, coagulopathy, and multiple organ dysfunction syndrome.
C. Sua´rez et al. / International Journal of Infectious Diseases 14S (2010) e73–e78 e7568 years (range 18–94 years). The infection was nosocomially
acquired in 79 of the episodes, 45 of them in the ICU. Thirty-three
episodes (27%) were caused by CRPA and 88 (73%) by carbapenem-
susceptible P. aeruginosa (CSPA) strains. Data for both groups are
summarized in Table 1. Patients in the CRPA group had been
hospitalized longer before the onset of bacteremia (median of 19
days vs. 9 days; p = 0.03) and had had a higher use of prior
antimicrobial therapy (97% vs. 66%; p < 0.001) over a longer time
period (14 vs. 7 days of antimicrobial therapy; p < 0.001),Table 2
Comparison of non-attributable death and attributable death in patients with Pseudom
Characteristic Survival/non-attributable death (n = 84)
Sex (male) 67 (80%)
Age, years (SD) 66 (16)
Acquisition
Nosocomial 54 (64%)
Healthcare/community 30 (36%)
ICU acquisition 30 (36%)
Carbapenem resistance 22 (26%)
Charlson index >2 31 (37%)
Polymicrobial bacteremia 19 (23%)
Source of bacteremia
Low-risk source 55 (66%)
High-risk source 29 (35%)
Severe sepsisa 14 (17%)
Antimicrobial therapyb
Empirical therapy
Appropriate 51 (65%)
Inappropriate 28 (35%)
Deﬁnitive therapy
Appropriate 67 (89%)
Inappropriate 8 (11%)
Non-antimicrobial therapy 46 (55%)
RR, relative risk; CI, conﬁdence interval; SD, standard deviation; ICU, intensive care un
a Severe sepsis also includes septic shock, coagulopathy, and multiple organ dysfunc
b Patients not receiving empirical antimicrobial treatment were excluded from thesecompared with patients in the CSPA group. Moreover, patients in
the CSPA group were more likely to have received appropriate
empirical antibiotic therapy (65% vs. 33%; p = 0.004). Fourteen
patients in the cohort did not receive empirical antimicrobial
therapy: six of them had a low-risk source of bacteremia (ﬁve had
catheter-related bacteremia and one had a urinary tract obstruc-
tion) and had received effective non-antimicrobial therapies as
treatment; four patientswere seriously ill or had severe underlying
conditions and received only palliative treatment; the remainingonas aeruginosa bacteremia
Attributable death (n = 37) RR (95% CI) p-Value
29 (78%) 1.0 (0.8–1.2) 0.86
66 (10) 0.79
25 (68%) 1.1 (0.8–1.4) 0.73
12 (32%)
15 (41%) 1.1 (0.7–1.8) 0.61
11 (30%) 1.1 (0.6–2.1) 0.69
20 (54%) 1.5 (0.9–2.2) 0.08
12 (32%) 1.4 (0.8–2.6) 0.26
8 (22%)
29 (78%) 2.3 (1.6–3.2) <0.001
32 (87%) 5.2 (3.2–8.5) <0.001
17 (61%) 0.9 (0.7–1.3) 0.72
11 (39%)
8 (73%) 0.8 (0.6–1.2) 0.15
3 (27%)
8 (22%) 0.4 (0.2–0.8) <0.001
it.
tion syndrome.
analyses (see text).
Table 3
Logistic regression models showing risk factors for 7-day mortality in 121 episodes of Pseudomonas aeruginosa bacteremia
Variables Model 1a Model 2b
OR (95% CI) p-Value OR (95% CI) p-Value
Carbapenem resistance 1.8 (0.5–6.8) 0.41 0.8 (0.2–4.6) 0.85
Severe sepsisc 38 (10.2–142.2) <0.001 66.1 (11.5–380.1) <0.001
High-risk focus 6.6 (1.6–26.9) 0.009 13.9 (2.4–79.9) 0.003
Non-antimicrobial therapy 0.3 (0.09–1.3) 0.120 0.5 (0.1–2.4) 0.4
Appropriate empirical antimicrobial therapy 0.22 (0.04–1.3) 0.088
OR, odds ratio; CI, conﬁdence interval.
Multivariate analyses using logistic regression model. All models are adjusted for age, sex and Charlson index.
a Model 1: all the episodes in the cohort were included in the analyses (N = 121).
b Model 2: excluding 14 episodes with no empirical antimicrobial therapy.
c Severe sepsis also includes patients with septic shock, coagulopathy, and multiple organ dysfunction syndrome.
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reasons.
3.2. Clinical outcomes and factors inﬂuencing mortality
Forty-seven patients (39%) died during the ﬁrst 30 days of
hospitalization, and 37 of them had a bacteremia-related death.
Baseline characteristics of patients who had attributable mortality
were similar to those of patientswho survived or had a non-related
death (Table 2), except for a more common high-risk focus as the
origin of the bacteremia and a clinical presentation with severe
sepsis in the former group. Multivariate analyses conﬁrmed that
the source of bacteremia and the severity of the clinical
presentation were independent factors predictive of death from
P. aeruginosa bloodstream infection (Table 3).
In addition, although the attributable mortality was similar in
both groups (33% in CRPA vs. 30% in CSPA; p = 0.69), the Kaplan–
Meier survival analysis (Figure 1) showed signiﬁcant differences in
the cumulative probability of death in the ﬁrst 48 h after
bacteremia; the cumulative probabilities of death at the end of
this period were 13% for CRPA and 50% for CSPA (p = 0.026).Figure 1. Kaplan–Meier probability estimate for attributable mortality of
Pseudomonas aeruginosa bacteremia according to carbapenem susceptibility. The
solid line represents patients with bacteremia caused by carbapenem-resistant P.
aeruginosa strains; the broken line represents patients with carbapenem-
susceptible P. aeruginosa strains.4. Discussion
In our study, patients with carbapenem-resistant P. aeruginosa
bacteremia had higher overall mortality (46% vs. 36%; p = 0.36), but
similar attributable mortality (33% vs. 30%; p = 0.69) than those
with carbapenem-susceptible strains. With respect to the epide-
miological characteristics, no differences in either underlying
diseases or the severity of clinical presentation at the onset of
bacteremia were observed between the two groups, but the
proportion of low-risk focus as a source of the bacteremia was
somewhat higher in the CRPA group. Logistic regression analyses
identiﬁed the presence of severe sepsis and a high-risk origin of
bacteremia as independent predictors of attributable death.
However, contrary towhatmight be expected, the appropriateness
of empirical antimicrobial therapy according to in vitro suscepti-
bility was not selected as a protective factor for mortality in the
whole group of patients with P. aeruginosa bacteremia.
Prior studies have also demonstrated that the source of
bacteremia and severity of illness at the time of bacteremia, like
the presence of septic shock, are associated with a poor prognosis
in cases of P. aeruginosa infection.1,3,12,13,20,24–33 However, the
relationship between appropriateness of empirical antimicrobial
therapy and mortality in P. aeruginosa bacteremia is controversial.
It is presumed that infections caused by antibiotic-resistant
microorganisms result in higher mortality than those caused by
susceptible strains, on the basis of the theoretically greater
likelihood of receiving inappropriate antimicrobial therapy.
Nevertheless, despite this intuitive perception and the association
between antibiotic resistance and worse outcome found in
previous studies,8,9,34 the causality of this relationship remains
unclear.10,11 In fact, previous classic studies, performed in both the
general population35 and in critically ill patients,36–38 have
demonstrated greater hospital mortality among patients with
inappropriate antimicrobial treatment of their infections, includ-
ing patients with bacteremia caused by P. aeruginosa20,25,30–32 and
other microorganisms,28 but this has not been conﬁrmed by other
studies14,15,39 Other factors depending on the virulence of the
microorganism or the characteristics of the host itself, which were
notmonitored in this study, should be considered in the analysis of
the relationship between treatment and mortality.40
In our study, the appropriateness of empirical therapy showed a
tendency towards a protective effect on mortality, although
without statistical signiﬁcance. This lack of signiﬁcant association
between inadequate empirical antibiotic therapy and outcomes
may be partly due to the incidence of other factors, such as the
source of the bacteremia. In fact, 60% of CRPA episodes were of
urinary or vascular catheter origin, in which non-antimicrobial
interventions such as catheter removal or decompression of
urinary obstruction are of critical importance in the treatment, and
might lead the antimicrobial therapy to a secondary role in that
C. Sua´rez et al. / International Journal of Infectious Diseases 14S (2010) e73–e78 e77group of infections. On the other hand, although in our study there
were no differences in the collected epidemiological character-
istics, patients with antimicrobial-resistant microorganisms are
known to have an impaired health status and a longer hospital stay,
increasing the possibility of death related to other concomitant
illnesses.
One of the most interesting ﬁndings of our study was that the
dynamics ofmortality differed between the CRPA and CSPA groups.
This new information may be valuable for the interpretation of the
way carbapenem resistance affects themortality of patientswith P.
aeruginosa bacteremia. Thus, although appropriateness of empiri-
cal treatment was lower among patients with CRPA bacteremia,
this group had a slower death than the CSPA group in the ﬁrst 48 h
after the bacteremia. These results might suggest a lower virulence
of carbapenem-resistant P. aeruginosa strains40 and could explain,
at least in part, why there is no clear evidence that inappropriate
antimicrobial treatment affects mortality in the whole group of
patients with P. aeruginosa bacteremia. We hypothesize that in a
subgroup of patients with infection due to CSPA strains, the
empirical antimicrobial treatment, even if appropriate, would not
interrupt the inﬂammatory response generated by its high
virulence. In contrast, in some patients with bacteremia caused
by carbapenem-resistant strains, with supposedly lower virulence,
a certain delay in appropriate antimicrobial therapy would not
have such deleterious effects on mortality. Similar results have
been published recently, suggesting that delays of up to 48–72 h in
receiving appropriate antibiotics do not affect the mortality of
patients with P. aeruginosa bacteremia.33,41,42
Several potential limitations should be considered in the
interpretation of the results of our study. First, since the study
was retrospective, we cannot rule out unmeasured confounding
factors. Another limitation is the small size of the population
studied, which decreases the statistical power of our results, as
only a few patients in each category of treatment were included in
the multivariate analyses.
In conclusion, patients with carbapenem-resistant P. aeruginosa
bacteremia had similar attributable death but initial slower death
than patients in the carbapenem-susceptible group. Having high-
risk sources of bacteremia and clinical presentation with severe
sepsis were identiﬁed as independent predictors of attributable
death in patients with P. aeruginosa bacteremia. The ﬁnding of the
relative non-relevance of the appropriateness of empirical
antibiotic therapy in patients with CRPA bacteremia is important
in drawing up nosocomial antibiotic policies. However, it might be
expected that therewould be a group of patients with P. aeruginosa
bacteremia in which the appropriateness of empirical treatment is
really relevant. Therefore, further larger studies are needed to
clarify this point and to conﬁrm our results.
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